Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
calmangafodipir + acetylcysteine
- Development stage
- Phase 1
- Lead developer
- Egetis Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**calmangafodipir + acetylcysteine** is a combination therapy under investigation for treating paracetamol (acetaminophen) overdose. Calmangafodipir acts as a superoxide dismutase mimetic (SOD mimetic) designed to protect against oxidative stress and hepatotoxicity. Acetylcysteine is the established antidote for acetaminophen overdose, functioning primarily by replenishing hepatic glutathione and promoting the detoxification of reactive metabolites. Combining calmangafodipir with acetylcysteine may offer enhanced protection of liver cells, particularly in patients at higher risk for liver injury or presenting later after overdose, by mitigating oxidative damage and reducing biomarkers of hepatotoxicity[1][3][7].
- Other names
- calmangafodipir + NAC
02
Targets
GSH (Glutathione synthesis / redox)
Beyond the preview
Go deeper on calmangafodipir + acetylcysteine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on calmangafodipir + acetylcysteine.